News >

Expert Assesses Available Treatments in CLL

Caroline Seymour
Published: Thursday, May 17, 2018

Ryan W. Jacobs, MD

Ryan W. Jacobs, MD
There have been major breakthroughs in the treatment of patients with chronic lymphocytic leukemia (CLL), explained Ryan W. Jacobs, MD, such as the addition of the small molecule inhibitors ibrutinib (Imbruvica), venetoclax (Venclexta), and idelalisib (Zydelig).

State of the Science Summit™ on Hematologic Malignancies, Jacobs, a physician of Levine Cancer Institute, discussed the use of small molecule inhibitors in the treatment of patients with CLL.

OncLive: How have these inhibitors impacted the treatment paradigm?

Jacobs: In the frontline setting, ibrutinib is still the only small molecule inhibitor that is approved by the FDA. When you're talking about use of novel treatments in the frontline setting, you're specifically making decisions between chemoimmunotherapy that we have used for years and ibrutinib, which has been FDA approved in the frontline setting since 2016.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication